Checkpoint Therapeutics (OTCQX:CKPT) is taking an “aggressive path forward” with its clinical programs and expects to be in registration studies at the end of 2018 with its lead targeted anti-cancer agent, CK-101, and lead immuno-oncology (IO) agent, CK-301.
Lion Biotechnologies (NASDAQ:LBIO) is establishing a leading position in immuno-oncology through its tumor-infiltrating lymphocyte (TIL) technology to deliver personalized oncology therapies to patients with unmet medical needs.
Ortho Regenerative Technologies is developing a “sticky scaffold” biologic that has the potential to be best in class to repair symptomatic lesions in shoulder tendons, knee meniscus and articular cartilage.
After nearly a decade of R&D, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is now conducting a pilot commercial launch of its TULSA-PRO medical device to ablate tissue in localized prostate cancer in key European and other CE Mark jurisdictions ahead of full commercialization.
Closely-held Vyome Biosciences expects to enroll the final patient next month in a proof-of-concept clinical trial in the U.S. of its lead molecule for drug-resistant acne, VB 1953.
Histogenics (NASDAQ:HSGX) expects to complete enrollment by the end of the second quarter this year in a Phase 3 clinical trial of its NeoCart biologic cell therapy and tissue engineering solution for knee cartilage regeneration.
Arch Therapeutics (OTCQB:ARTH) has multiple regulatory filings planned in the U.S. and Europe this year for its AC5 Topical Hemostatic Device as the biopharma company shifts to regulatory-stage footing ahead of commercialization.
Roth Capital Partners raised its price target for Conatus Pharmaceuticals (NASDAQ:CNAT) to $12 from $4, reflecting a revised valuation. The stock closed at $7.58 on April 21.
Canadian scientists say they have discovered the first new antibiotic in three decades, and that their research suggests it may potentially be effective at killing two worrisome superbugs: Pseudomonas aeruginosa and Neisseria gonorrhoea.
BTIG initiated coverage of Cascadian Therapeutics (NASDAQ:CASC) with a “buy” rating and $13 price target. The stock closed at $3.92 On April 20.
Duff & Phelps has added managing director Phil Smith and director Adam Stormoen to its healthcare M&A advisory practice in Minneapolis.
Titan Pharmaceuticals (NASDAQ:TTNP) and its marketing partner, closely-held Braeburn Pharmaceuticals, received a potential shot in the arm as the White House called for expanded access to treatment in the war on opioid addition.
Roth Capital Partners launched coverage of Zafgen (NASDAQ:ZFGN) with a “buy” rating and $9 price target. The stock closed at $4.90 on April 19.
Closely-held ZappRx closed a $25-million Series B funding led by Qiming US Healthcare Fund, with participation from SR One, which led ZappRx’s Series A round in 2014, and GV, formerly Google Ventures.
Roth Capital Partners initiated coverage of Poxel SA (NXT:PA) with a “buy” rating and price target of €11. The stock was recently quoted at €5.14.